Sri International

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Nocicepta LLC

Astraea Therapeutics, LLC

Lawrence Robert Toll

Irving William Wainer

Michel Bernier

Lucita Arenas Jimenez

Patrick Denis Lincoln

Daniel Jacobs

David C Yeomans

Nurulain Zaveri

Martin S Angst

Faming Jiang

Peter D Karp

Kemal Sonmez

Ronald G Almquist

Cris M Olsen

Taline Khroyan

Willma E Polgar

This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogues for the treatment of a tumor expressing a &#x3b2;2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a &#x3b2;2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analogue or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.

Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a &#x3b2;2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a &#x3b2;2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.

Provided herein are novel and selective high affinity &#x3b1;3&#x3b2;4 nicotinic acetycholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the &#x3b1;3&#x3b2;4 nicotinic acetycholine receptor using the compounds and compositions disclosed herein.

Selective high affinity &#x3b1;3&#x3b2;4 nicotinic acetylcholine receptor antagonists

The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.

Methods for treatment of pain

The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 11-membered azabicyclo ring.

Nicotinic acetylcholine receptor modulators

Disclosed are methods, software, and systems for comparing biopolymer sequences. The model includes at least two different characterizations of states of matching between segments of sequences at defined positions. Examples of states of matching include: similarity and dissimilarity between objects, as well as similarity to a reference, e.g., a reference sequence or a sequence profile. A topology of particular match states can be used to identify classes of sequences, e.g., preprohormone sequences.

Biopolymer sequence comparison

A model is used to represent a set of structured data objects that include elements at defined positions. The model includes distributions of vectors, each distribution corresponding to particular positions in the respective structured data objects, each of the vectors comprising values for the particular positions; and comparing a given set of structured data objects to the model to determine a likelihood that the given set is represented by the model. At least some of the distributions of the model differ such that different states of matching are indicated. Distributions of the model can indicate: dissimilarity between the structured data objects at defined positions; similarity between the structured data objects at defined positions; or similarity to a reference structure data object at defined positions.

Data relationship model

A novel atrial peptide-degrading enzyme (ADE) is provided in isolated, purified form. The enzyme has a molecular weight of approximately 160,000 Daltons as measured by gel filtration chromatography, and is effective to cleave atrial peptides such as APII, APIII and ANF. Also provided are novel compounds useful as inhibitors of the enzyme and thus useful as blood pressure lowering agents, pharmaceutical compositions containing the inhibitors, and methods of using the inhibitors.

Growing community of inventors

Redwood City, CA, United States of America

Lawrence Robert Toll